コンテンツへスキップ
Merck

GE17-1440-02

Ficoll® Paque Plus

Cytiva 17-1440-02, pack of 6 × 100 mL

別名:

Ficoll density gradient medium, cell culture media

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12352201
NACRES:
NA.25

フォーム

liquid

包装

pack of 6 × 100 mL

メーカー/製品名

Cytiva 17-1440-02

Colorless to slightly yellow

pH範囲

5.5-7.5

詳細

Ficoll-Paque Plus is a recognized standard in laboratories worldwide for the isolation of human lymphocytes for in vitro studies.

Ficoll-Paque PLUS is a ready to use, sterile medium for isolation of lymphocytes in high yield from peripheral blood using a simple and rapid centrifugation procedure. It maintains the viability and a representative distribution of B and T lymphocytes.

アプリケーション

For in vitro isolation of lymphocytes from human peripheral blood.

特徴および利点

  • Ready to use sterile medium for isolation of human lymphocytes in high yield from peripheral blood.
  • Maintains viability and representative distribution of B and T lymphocytes.
  • Low levels of endotoxin (< 0.12 EU/mL).

保管および安定性

Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.
Store at 4 to 30 °C ()

アナリシスノート

この製品の分析証明書は、www.cytiva.com.

法的情報

Ficoll is a registered trademark of Cytiva

ピクトグラム

Flame

シグナルワード

Danger

危険有害性情報

危険有害性の分類

Flam. Liq. 2

保管分類コード

3 - Flammable liquids

WGK

WGK 3


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

この製品を見ている人はこちらもチェック

Slide 1 of 3

1 of 3

Mehdi Hassanpour et al.
Stem cell research & therapy, 11(1), 139-139 (2020-03-29)
To date, many attempts are employed to increase the regenerative potential of stem cells. In this study, we evaluated the hypothesis of whether an autophagy modulation could alter differentiation potency of CD146+ cells into mature pericyte, endothelial, and cardiomyocyte lineage.
Matthew A Lakins et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(15), 4154-4167 (2020-04-30)
With the increased prevalence in checkpoint therapy resistance, there remains a significant unmet need for additional therapies for patients with relapsing or refractory cancer. We have developed FS222, a bispecific tetravalent antibody targeting CD137 and PD-L1, to induce T-cell activation
Jingyong Li et al.
Arteriosclerosis, thrombosis, and vascular biology, 39(3), 446-458 (2019-01-18)
Objective- Inflammation occurs during the progression of abdominal aortic aneurysm (AAA). IL (interleukin)-33 is a pleiotropic cytokine with multiple immunomodulatory effects, yet its role in AAA remains unknown. Approach and Results- Immunoblot, immunohistochemistry, and immunofluorescent staining revealed increased IL-33 expression
Hagen Schwenzer et al.
Cell reports, 26(12), 3416-3428 (2019-03-21)
In eukaryotes, tRNAs are transcribed in the nucleus and exported to the cytosol, where they deliver amino acids to ribosomes for protein translation. This nuclear-cytoplasmic movement was believed to be unidirectional. However, active shuttling of tRNAs, named tRNA retrograde transport
Rajan George et al.
Human vaccines & immunotherapeutics, 16(4), 779-792 (2019-11-07)
Chimigen® HBV Immunotherapeutic Vaccine (C-HBV), a recombinant chimeric fusion protein comprising hepatitis B virus (HBV) S1 and S2 surface antigen fragments, Core antigen and a murine monoclonal antibody heavy chain fragment (Fc), was designed and produced in Sf9 insect cells.

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)